Celltrion Holdings IPO

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

South Korea’s top four financial holding companies – Shinhan, KB, Hana and Woori – reported stellar earnings for the first quarter...

LG Electronics Inc. is mulling putting off an initial public offering of its wholly owned subsidiary in India amid growing volatility in the global ...

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Hylium Industries Inc., South Korea’s hydrogen liquefier manufacturer, has signed a deal to supply high-capacity liquefied hydrogen storage ta...

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Kakao Corp., South Korea’s largest mobile platform, is looking to sell a majority stake in Kakao Entertainment Corp., dropping a plan to take ...

Kakao Entertainment Corp. has been divesting unprofitable music labels and digital content platforms, which it has gobbled up over the past few year...

LG Electronics Inc. is set to list its wholly owned subsidiary in India on the country's stock exchange in early May, aiming to raise up to $1.5 bil...

South Korea’s Constitutional Court permanently removed President Yoon Suk Yeol from office on Friday, making him the country’s second pr...

South Korea’s Constitutional Court on Friday will give its ruling on President Yoon Suk Yeol, who was impeached in December for declaring mart...

South Korea’s chemical-to-defense conglomerate Hanwha Group Chairman Kim Seung-youn will hand over half of his holdings in the conglomerate&rs...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

South Korea’s National Pension Service (NPS), the world’s third-largest pension fund, has agreed to buy a stake in Australian asset mana...

South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of treasury shares to i...

Hanwha Energy Corp., wholly owned by Hanwha Group Chairman Kim Seung-youn’s three sons, has embarked on the process of going public – a ...

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...

Affinity Equity Partners and Singapore’s sovereign wealth fund GIC have sold their entire stake in Kyobo Life Insurance Co., exiting from thei...

Seoul Guarantee Insurance Co. (SGI) will raise 181.5 billion won ($124.2 million) through an initial public offering later this month in its second ...

LG Group Chairman Koo Kwang-mo visited LG Electronics Inc.'s factory and research center in India in late February as it plans to list its Indian ar...

CHA Biotech Co., South Korea’s leading stem cell therapeutics developer, plans to resume an initial public offering of CHA Healthcare Co., a m...

LG Electronics Inc. posted its largest-ever sales in India in 2024, providing a boost to the planned initial public offering of its Indian unit this...

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Meritz Financial Group Inc., once a medium-sized financial service firm in South Korea, has become the second-most valuable publicly traded financia...

Global private equity firm KKR & Co. Inc. has succeeded in cashing out of its stake in HD Hyundai Marine Solution Co. for 295 billion won ($206 ...

Meritz Financial Group Inc. has reported its best-ever net profit for last year thanks to handsome gains from investments by its insurance and secur...

Companies in South Korea are expected to refrain from seeking initial public offerings for a while after the country’s much-anticipated new bl...

KB Financial Group Inc., South Korea’s largest financial holding group, will spend nearly 1.8 trillion won ($1.2 billion) to boost shareholder...

South Korean companies are relaunching attempts to go public with lower valuations and fewer shares amid continued sour investor sentiment.CK Soluti...

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...